JPRN-jRCT2080222010
Unknown
Phase 3
An Extension Study in Subjects with Plaque Psoriasis
Kyowa Hakko Kirin Co., Ltd.0 sites100 target enrollmentJanuary 28, 2013
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Enrollment
- 100
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject has voluntarily signed the written informed consent form to participate in this study
- •\- Subject has completed the week 12 evaluation of Study 4827\-002
Exclusion Criteria
- •\- Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)
- •\- Subject has been judged to be ineligible for participation in the study by the investigators/subinbestigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
M518101 phase III study in plaque psoriasis patientsPlaque psoriasisJPRN-jRCT2080222894Maruho Co.,Ltd.
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 2Plaque psoriasisJPRN-jRCT2080221434Maruho Co.,Ltd.
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 1JPRN-jRCT2080221433Maruho Co.,Ltd.
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 3JPRN-jRCT2080222091Maruho Co.,Ltd.
Completed
Not Applicable
A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)Moderate Plaque PsoriasisNCT03059953Genesis Pharma S.A.302